Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis

Abstract Etrolizumab is an IgG1‐humanized monoclonal anti‐β7 integrin antibody. Phase III trials with induction and/or maintenance phases were conducted in patients with moderately‐to‐severely active ulcerative colitis (UC) who were either previously treated with tumor necrosis factor (TNF) inhibito...

Full description

Saved in:
Bibliographic Details
Main Authors: Nastya Kassir (Author), Rui Zhu (Author), Anita Moein (Author), Jurgen Langenhorst (Author), Jakob Ribbing (Author), Rong Zhang (Author), Meina T. Tang (Author), Young S. Oh (Author), Wenhui Zhang (Author)
Format: Book
Published: Wiley, 2022-09-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available